Financing led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, with participation by new and current healthcare investors Funds to support Phase 2b development of AP01 and Phase 2a development of AP02 for pulmonary fibrosis SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, announced the closing of an oversubscribed $175 million Series C financing.

由Perceptive Xontogeny Venture Funds，SR One和Eventide资产管理领导的融资，新的和当前的医疗保健投资者资金参与，以支持AP01的2b期开发和AP02的2a期开发，用于肺纤维化西雅图，2023年9月27日（GLOBE NEWSWIRE）-Avalyn Pharma Inc。，一家临床阶段的生物制药公司专注于开发针对威胁生命的肺部疾病的靶向吸入疗法，宣布关闭一项超额1.75亿美元的C系列融资。

Avalyn plans to use the funds to continue development of its portfolio of inhalation therapies for interstitial lung disease that improve upon currently approved medications, and advance lead clinical assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), into mid-stage clinical trials. The Series C financing was co-led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, which were joined by new investors, Vida Ventures, Wellington Management, Rock Springs Capital, funds and accounts advised by T.

Avalyn计划利用这些资金继续开发其间质性肺病吸入疗法组合，以改进目前批准的药物，并将主要临床资产AP01（吸入吡非尼酮）和AP02（吸入nintedanib）推进中期临床试验。C系列融资由Perceptive Xontogeny Venture Funds，SR One和Eventide Asset Management共同领导，新投资者，Vida Ventures，Wellington Management，Rock Springs Capital，资金和T.建议的账户共同参与。

Rowe Price Associates, Inc., Surveyor Capital (a Citadel Company), Catalio Capital Management, and Piper Heartland. Current investors, including Novo Holdings A/S, Norwest Venture Partners, F-Prime Capital, Pivotal bioVenture Partners, and RiverVest Venture Partners, also participated. In conjunction with the financing, Gianna Hoffman-Luca, Ph.D., of Perceptive Xontogeny Venture Funds, and Jill Carroll of SR One, joined Avalyn’s Board of Directors.

Rowe Price Associates，Inc.，Surveyor Capital（一家城堡公司），Catalio Capital Management和Piper Heartland。目前的投资者，包括Novo Holdings A/S，Norwest Venture Partners，F-Prime Capital，Pivotal bioVenture Partners和RiverVest Venture Partners也参加了会议。在融资的同时，Perceptive Xontogeny Venture Funds的Gianna Hoffman-Luca博士和SR One的Jill Carroll加入了Avalyn的董事会。

“Pulmonary fibrosis is a fatal disease with a median survival of only 3-5 years. Fewer than 30% of patients in the U.S. are treated with either of the two approved oral medicines today due to their significant tolerability challenges,” said Lyn Baranowski, CEO of Avalyn..

Avalyn首席执行官Lyn Baranowski说：“肺纤维化是一种致命疾病，中位生存期仅为3-5年，美国不到30%的患者由于其严重的耐受性挑战而今天接受两种经批准的口服药物中的任何一种治疗。。